Business
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patientsPosters now available on Allarity’s website TARPON SPRINGS, Fla., April 21, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathw
About this update from Allarity Therapeutics, Inc.
[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZWz91jG0GlKDMeDFLyVrBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"text","content":"","length":48,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulation","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"The Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patients","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Posters now available on Allarity’s website","length":43,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"text","content":"TARPON SPRINGS, Fla., April 21, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that it has published two scientific posters being presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22 in San Diego, California. Both are now available in the Scientific Publications section of the Company’s website.","length":543,"tagName":"p"},{"type":"text","content":"The two posters highlight new data supporting stenoparib’s differentiated mechanism of action as well as the Company’s proprietary Drug Response Predictor (DRP®) for stenoparib as a companion diagnostic platform.Poster presentations","length":234,"tagName":"p"},{"type":"text","content":"Poster 1Title: A Drug Response Predictor (DRP®) is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with 2X-121/stenoparib (NCT03878849)Session Title: Biomarkers Predictive of Therapeutic Benefit 3Session Time: April 20, 2026, 9:00 AM – 12:00 PM","length":331,"tagName":"...